Last updated on October 2018

A Multicenter 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar Gel in Subjects With Rheumatoid Arthritis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Rheumatoid Arthritis
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Subjects must meet criteria for rheumatoid arthritis as defined by 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification at screening.
  2. Subjects must have persistently active rheumatoid arthritis defined as DAS 28-ESR > 3.2 at screening.
  3. Subjects must have been on a corticosteroid 12 weeks prior to screening, with a stable dose of 5-10 mg prednisone (or prednisone equivalent) for 4 weeks prior to screening.
  4. Subjects must have been on either a non-biologic or biologic treatment in the 12 weeks prior to screening.

Exclusion Criteria:

  1. Subjects cannot have used intra-articular steroids within 14 days of the screening visit.
  2. Subjects cannot have any known contraindication to Acthar.
  3. Subjects cannot have Type 1 or Type 2 diabetes.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.